<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545232</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-GEN-11-0174</org_study_id>
    <secondary_id>U01HL077863</secondary_id>
    <nct_id>NCT01545232</nct_id>
  </id_info>
  <brief_title>Pragmatic, Randomized Optimal Platelet and Plasma Ratios</brief_title>
  <acronym>PROPPR</acronym>
  <official_title>Pragmatic, Randomized Optimal Platelet and Plasma Ratios</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Resuscitation Outcomes Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Defence Research and Development Canada</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial
      designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted
      to receive massive transfusion ([MT] (defined as receiving 10 units or more red blood cells
      (RBCs) within the first 24 hours). The goal of PROPPR is to improve the basis on which
      clinicians make decisions about transfusion protocols for massively bleeding patients.

      PROPPR is a Resuscitation Outcomes Consortium (ROC) Protocol. ROC is funded by the National
      Heart, Lung, and Blood Institute (NHLBI), the United States' Department of Defense (DoD) and
      the Defence Research and Development Canada. PROPPR will be conducted as a Phase III trial at
      Level I Adult Trauma Centers in North America.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Multiple observational studies have reported that blood product component ratios
      (i.e., plasma:platelets:RBCs) that approach the 1:1:1 ratio, found in fresh whole blood, are
      associated with significant decreases in truncal hemorrhagic death and in overall 24-hour and
      30-day mortality among injured patients. The rationale for the 1:1:1 ratio is that the closer
      a transfusion regimen approximates whole blood, the faster hemostasis will be achieved with
      minimum risk of coagulopathy. The current DoD guideline specifies the use of 1:1:1, and this
      practice is followed on almost all combat casualties. In other observational studies, leading
      centers have reported good outcomes across a range of different blood product ratios. For
      example, a 1:2 plasma:RBC ratio is used with little guidance regarding platelets. The
      proposed randomized trial is intended to resolve debate and uncertainty regarding optimum
      blood product ratios.

      Study Design: Randomized, two-group, controlled Phase III trial with a Vanguard stage. Equal
      random allocation to treatment using stratified, permuted blocks with randomly chosen block
      sizes and stratification by site.

      Objective: To conduct a Phase III multi-site, randomized trial in subjects predicted to have
      a massive transfusion, comparing the efficacy and safety of 1:1:1 transfusion ratios of
      plasma and platelets to red blood cells (the closest approximation to reconstituted whole
      blood) with the 1:1:2 ratio. The co-primary outcomes will be 24-hour and 30-day mortality.
      The PROPPR Trial will be conducted with exception from informed consent (EFIC). Additionally,
      laboratory data from the trial will add to the understanding of trauma induced coagulopathy
      (TIC) and inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Mortality</measure>
    <time_frame>First 24 hours after ED admission</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>First 30 days after ED admission</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Coagulation and Inflammatory Phenotypes at Emergency Department Admission and Over Time.</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Free Days</measure>
    <time_frame>first 30 days after ED admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>ED admission to hospital discharge or 30 days, whichever comes first</time_frame>
    <description>Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete)following emergency department (ED) arrival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Randomized Blood Products Given to Hemostasis</measure>
    <time_frame>24 hours from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status at Time of Hospital Discharge</measure>
    <time_frame>Hospital discharge or 30 days, whichever comes first</time_frame>
    <description>The Glasgow Outcome Extended Score (GOSE) is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Primary Surgical Procedure</measure>
    <time_frame>ED admission to hospital discharge or 30 days, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Transfusion Related Serious Adverse Events</measure>
    <time_frame>ED admission to hospital discharge or 30 days, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial Hospital Discharge Status</measure>
    <time_frame>Hospital discharge or 30 days, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days</measure>
    <time_frame>first 30 days after ED admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Free Days</measure>
    <time_frame>first 30 days after ED admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Blood Products Given From Hemostasis to 24 Hours After ED Admission</measure>
    <time_frame>24 hours after ED admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">680</enrollment>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>1:1:1 Blood Transfusion Ratio</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1:1:2 Blood Transfusion Ratio</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1:1:1 Blood Transfusion Ratio</intervention_name>
    <description>Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
    <arm_group_label>1:1:1 Blood Transfusion Ratio</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1:1:2 Blood Transfusion Ratio</intervention_name>
    <description>Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
    <arm_group_label>1:1:2 Blood Transfusion Ratio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who require the highest trauma team activation at each participating center,

          -  Estimated age of 15 years or older or greater than/equal to weight of 50 kg if age
             unknown,

          -  Received directly from the injury scene,

          -  Initiated transfusion of at least one unit of blood component within the first hour of
             arrival or during prehospital transport, and

          -  Predicted to receive a MT by exceeding the threshold score of either the Assessment of
             Blood Consumption (ABC) score or the attending trauma physician's judgment criteria

        Exclusion Criteria:

          -  Received care (as defined as receiving a life saving intervention) from an outside
             hospital or healthcare facility (Procedures and care given at an outside health
             facility cannot be documented or controlled resulting in a high variability of
             standards of care and clinical outcomes.)

          -  Moribund patient with devastating injuries and expected to die within one hour of
             Emergency Department (ED) admission

          -  Prisoners, defined as those who have been directly admitted from a correctional
             facility

          -  Patients requiring an emergency thoracotomy

          -  Children under the age of 15 years or under 50 kg body weight if age unknown

          -  Known pregnancy in the ED

          -  Greater than 20% total body surface area (TBSA) burns

          -  Suspected inhalation injury

          -  Received greater than five consecutive minutes of cardiopulmonary resuscitation (CPR
             with chest compressions) in the pre-arrival or ED setting

          -  Known Do Not Resuscitate (DNR) prior to randomization

          -  Enrolled in a concurrent, ongoing interventional, randomized clinical trial

          -  Patients who have activated the &quot;opt-out&quot; process or patients/legally authorized
             representatives that refuse blood products on arrival to ED.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Holcomb, MD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center- Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington- Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://roc.uwctc.org/tiki/tiki-index.php</url>
    <description>ROC web site</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <results_first_submitted>April 22, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2015</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>John Holcomb</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <keyword>Massive Transfusion</keyword>
  <keyword>Trauma</keyword>
  <keyword>Coagulopathy</keyword>
  <keyword>Trauma Induced Coagulopathy</keyword>
  <keyword>Plasma</keyword>
  <keyword>Platelets</keyword>
  <keyword>Red Blood Cells</keyword>
  <keyword>Mortality</keyword>
  <keyword>Wounds and Injuries</keyword>
  <keyword>Shock, Hemorrhagic</keyword>
  <keyword>Shock</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Hemostatics</keyword>
  <keyword>Coagulation</keyword>
  <keyword>Transfusion-related acute lung injury (TRALI)</keyword>
  <keyword>Inflammation</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1:1:1 Blood Transfusion Ratio</title>
          <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
        </group>
        <group group_id="P2">
          <title>1:1:2 Blood Transfusion Ratio</title>
          <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1:1:1 Blood Transfusion Ratio</title>
          <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
        </group>
        <group group_id="B2">
          <title>1:1:2 Blood Transfusion Ratio</title>
          <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="338"/>
            <count group_id="B2" value="342"/>
            <count group_id="B3" value="680"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>15 years of age or older</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="342"/>
                    <measurement group_id="B3" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="434"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24-hour Mortality</title>
        <time_frame>First 24 hours after ED admission</time_frame>
        <population>Number of subjects who were randomized to each group</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Mortality</title>
          <population>Number of subjects who were randomized to each group</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Initial sample size (580) planned to detect a clinically meaningful 10% difference in 24-hour mortality (11% vs. 21%) supported by prior data. Data Safety Monitoring Board (DSMB) increased sample size to 680 according to trial’s adaptive design. With 680 pts. &amp; given the final observed mortality proportions in 1:1:1 group, PROPPR had 95% power to detect the pre-specified 10% difference at 24 hours if such differences existed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>The critical level for significance (p&lt;0.044) was adjusted for two interim analyses, and all tests were conducted using two-sided tests.</method_desc>
            <param_type>Adjusted Relative Risk</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>30-day Mortality</title>
        <time_frame>First 30 days after ED admission</time_frame>
        <population>Number of subjects enrolled into each group.</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Mortality</title>
          <population>Number of subjects enrolled into each group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Initial sample size of 580 planned to detect clinically meaningful a 12% difference in 30-day mortality (23% vs. 35%),supported by prior data. DSMB increased sample size to 680 according to trial’s adaptive design. With 680 patients &amp; given final observed mortality proportions in the 1:1:1 group, PROPPR had 92% power to detect the pre-specified 12% difference at 30 days, if such differences existed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>The critical level for significance (p&lt;0.044) was adjusted for two interim analyses, and all tests were conducted using two-sided tests.</method_desc>
            <param_type>Adjusted Relative Risk</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Coagulation and Inflammatory Phenotypes at Emergency Department Admission and Over Time.</title>
        <time_frame>72 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Free Days</title>
        <time_frame>first 30 days after ED admission</time_frame>
        <population>Number of hospital free days for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Free Days</title>
          <population>Number of hospital free days for each group.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="17"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>van Elteren's test for medians</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hemostasis</title>
        <description>Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete)following emergency department (ED) arrival.</description>
        <time_frame>ED admission to hospital discharge or 30 days, whichever comes first</time_frame>
        <population>Time to anatomic hemostasis</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis</title>
          <description>Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete)following emergency department (ED) arrival.</description>
          <population>Time to anatomic hemostasis</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="64" upper_limit="179"/>
                    <measurement group_id="O2" value="100" lower_limit="56" upper_limit="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>van Elteren's test for medians</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Randomized Blood Products Given to Hemostasis</title>
        <time_frame>24 hours from randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Randomized Blood Products Given to Hemostasis</title>
          <units>units of blood products</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="32"/>
                    <measurement group_id="O2" value="15" lower_limit="5" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status at Time of Hospital Discharge</title>
        <description>The Glasgow Outcome Extended Score (GOSE) is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.</description>
        <time_frame>Hospital discharge or 30 days, whichever comes first</time_frame>
        <population>Glasgow Outcome Extended Score (GOSE) Score on discharged patients who had a head injury (Abbreviated Injury Score (AIS) &gt; 1) ranging from 1 to 8. The AIS is a coding scale to classify the injury severity. A score is created for each body region, type of anatomic structure (i.e. whole area, vessels,organs), and severity(minor to maximum).</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status at Time of Hospital Discharge</title>
          <description>The Glasgow Outcome Extended Score (GOSE) is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.</description>
          <population>Glasgow Outcome Extended Score (GOSE) Score on discharged patients who had a head injury (Abbreviated Injury Score (AIS) &gt; 1) ranging from 1 to 8. The AIS is a coding scale to classify the injury severity. A score is created for each body region, type of anatomic structure (i.e. whole area, vessels,organs), and severity(minor to maximum).</population>
          <units>units on the GOSE scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>van Elteren's test for medians</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Primary Surgical Procedure</title>
        <time_frame>ED admission to hospital discharge or 30 days, whichever comes first</time_frame>
        <population>Incidence of primary surgical procedure</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Primary Surgical Procedure</title>
          <population>Incidence of primary surgical procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Transfusion Related Serious Adverse Events</title>
        <time_frame>ED admission to hospital discharge or 30 days, whichever comes first</time_frame>
        <population>Incidence of transfusion related serious adverse events-Reportable to FDA</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Transfusion Related Serious Adverse Events</title>
          <population>Incidence of transfusion related serious adverse events-Reportable to FDA</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Hospital Discharge Status</title>
        <time_frame>Hospital discharge or 30 days, whichever comes first</time_frame>
        <population>Disposition of subject at time of hospital discharge</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Hospital Discharge Status</title>
          <population>Disposition of subject at time of hospital discharge</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained hospitalized at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morgue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>generalized logit model regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Free Days</title>
        <time_frame>first 30 days after ED admission</time_frame>
        <population>Number of ventilator free days for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days</title>
          <population>Number of ventilator free days for each group.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>van Elteren's test for medians</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Free Days</title>
        <time_frame>first 30 days after ED admission</time_frame>
        <population>Number of ICU free days for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Free Days</title>
          <population>Number of ICU free days for each group.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>van Elteren's test for medians</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Blood Products Given From Hemostasis to 24 Hours After ED Admission</title>
        <time_frame>24 hours after ED admission</time_frame>
        <population>Unit of measure for outcome measures below is median number of blood product units that given in each group (1:1:1 or 1:1:2) from time initial hemostasis was complete (PROPPR randomized study products stopped) up to 24 hours following ED admission. Number of participants is based on those who survived up to 24 hours, not participants randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>1:1:1 Blood Transfusion Ratio</title>
            <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
          <group group_id="O2">
            <title>1:1:2 Blood Transfusion Ratio</title>
            <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Blood Products Given From Hemostasis to 24 Hours After ED Admission</title>
          <population>Unit of measure for outcome measures below is median number of blood product units that given in each group (1:1:1 or 1:1:2) from time initial hemostasis was complete (PROPPR randomized study products stopped) up to 24 hours following ED admission. Number of participants is based on those who survived up to 24 hours, not participants randomized.</population>
          <units>units of blood products</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 30 days following ED admission</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1:1:1 Blood Transfusion Ratio</title>
          <description>1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.</description>
        </group>
        <group group_id="E2">
          <title>1:1:2 Blood Transfusion Ratio</title>
          <description>1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion-associated circulatory overload</sub_title>
                <description>Serious adverse event reportable to FDA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatremia associated with hypertonic saline use</sub_title>
                <description>Serious adverse events reportable to FDA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="297" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="338"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="265" subjects_affected="231" subjects_at_risk="338"/>
                <counts group_id="E2" events="239" subjects_affected="216" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Abdominal Complication</sub_title>
                <description>Also includes complications related to injury</description>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="338"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Multiple Organ Failure</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="338"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Additional bleeding after hemostasis requiring intervention</sub_title>
                <description>bleeding occurring after hemostasis requiring an interventional radiology or surgical procedure</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="338"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Abdominal Compartment syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Transfusion-related allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed serological transfusion reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Febrile nonhemolytic transfusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="110" subjects_affected="99" subjects_at_risk="338"/>
                <counts group_id="E2" events="102" subjects_affected="91" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Includes urinary tract infection, wound infection, line infection and other. Data is not available for the specific types of infection (i.e. urinary, wound, line).</description>
                <counts group_id="E1" events="155" subjects_affected="98" subjects_at_risk="338"/>
                <counts group_id="E2" events="146" subjects_affected="106" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Ventilator-associated pneumonia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="62" subjects_at_risk="338"/>
                <counts group_id="E2" events="65" subjects_affected="58" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion-related metabolic complications</sub_title>
                <description>Hypocalcemia and hyperkalemia only</description>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="338"/>
                <counts group_id="E2" events="60" subjects_affected="59" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="338"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="87" subjects_affected="74" subjects_at_risk="338"/>
                <counts group_id="E2" events="93" subjects_affected="85" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Lung Injury</sub_title>
                <counts group_id="E1" events="56" subjects_affected="47" subjects_at_risk="338"/>
                <counts group_id="E2" events="66" subjects_affected="57" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="55" subjects_affected="46" subjects_at_risk="338"/>
                <counts group_id="E2" events="57" subjects_affected="48" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Symptomatic pulmonary embolism</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="338"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="342"/>
              </event>
              <event>
                <sub_title>Asymptomatic pulmonary embolism</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="338"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="338"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="342"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Holcomb, M.D.</name_or_title>
      <organization>University of Texas Health Science Center - Houston</organization>
      <phone>713-500-5493</phone>
      <email>John.Holcomb@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

